Table 2.
CMV positive N = 27/tests = 48 |
CMV negative N = 118/tests = 197 |
p-Value | |
---|---|---|---|
Age at testing, median days (IQR) | 58 (51–74) | 47 (33–62) | < 0.001 |
Times tested per patient, N (%) | |||
1 | 15 (55.5) | 77 (65.3) | 0.59 |
2 | 6 (22.2) | 15 (12.7) | |
≥ 3 | 6 (22.2) | 26 (22.0) | |
Specimen tested, N (%) | |||
Urine | 43 (89.6) | 184 (93.4) | 0.20 |
Cerebrospinal fluid | 1 (2.1) | 2 (1.0) | |
Tracheal aspirate | 2 (4.2) | 1 (0.5) | |
Other | 2 (4.2) | 10 (5.1) | |
Indication for testing, N (%) | |||
Small for gestational age | 0 | 9 (7.6) | 0.14 |
Thrombocytopenia | 18 (66.6) | 37 (31.4) | < 0.001 |
Cholestasis | 8 (29.6) | 55 (46.6) | 0.11 |
Part of late-onset sepsis evaluation | 13 (48.2) | 44 (37.3) | 0.23 |
New cranial imaging abnormality | 1 (3.7) | 13 (11) | 0.25 |
Other indicationsa | 3 (11.1) | 11 (9.3) | 0.78 |
Incidence of abnormal laboratory values within ± 7 d of CMV test, N (%)b | |||
Platelet < 100,000 | 14 (51.9) | 27 (28.1) | 0.02 |
Leukocyte count < 5,000 | 2 (7.4) | 10 (10.5) | 1.0 |
Absolute neutrophil count < 1,000 | 11 (40.7) | 15 (15.8) | 0.005 |
Direct bilirubin > 1.0 | 7 (30.4) | 56 (67.5) | 0.001 |
Aspartate transaminase > 150 | 8 (33.3) | 20 (23.5) | 0.33 |
Alanine transaminase > 150 | 3 (12.5) | 5 (5.9) | 0.37 |
Abbreviations: CMV, cytomegalovirus; IQR, interquartile range.
Other indications among CMV-positive infants: rhinitis, hepatosplenomegaly, sibling tested for CMV. Among CMV-negative infants: retinal scarring, failed hearing screen, recurrent indirect bilirubinemia, rhinitis, diagnostic bronchial lavage sampling, liver calcifications, bloody stool, viral panel performed in response to breastmilk administration error, sibling tested for CMV.
Complete blood count was sent for 143 infants (27 CMV positive and 115 CMV negative), direct bilirubin in 106 infants (23 CMV positive and 83 CMV negative), liver transaminases in 109 infants (24 CMV positive and 85 CMV negative).